Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

A dual chicken IgY against rotavirus and norovirus.

Posted by on in 2013
  • Font size: Larger Smaller
  • Hits: 2893
  • Print

Dai YC, Zhang XF, Tan M, Huang P, Lei W, Fang H, Zhong W, Jiang X. 2012. Antiviral Res. 97:293-300. doi: 10.1016/j.antiviral.2012.12.011. [Epub ahead of print]

Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, Guangdong, China; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.


Rotavirus (RV) and norovirus (NoV) are the two most important causes of viral gastroenteritis. While vaccine remains an effective prophylactic strategy, development of other approaches, such as passive immunization to control and treat clinical infection and illness of these two pathogens, is necessary. Previously we demonstrated that high titers of NoV-specific IgY were readily developed by immunization of chickens with the NoV P particles. In this study, we developed a dual IgY against both RV and NoV through immunization of chickens with a divalent vaccine comprising neutralizing antigens of both RV and NoV. This divalent vaccine, named P-VP8(∗) particle, is made of the NoV P particle as a carrier with the RV spike protein VP8(∗) as a surface insertion. Approximately 45mg of IgY were readily obtained from each yolk with high titers of anti-P particle and anti-VP8(∗) antibodies detected by ELISA, Western blot, HBGA blocking (NoV and RV) and neutralization (RV) assays. Reductions of RV replication were observed with viruses treated with the IgY before and after inoculation into cells, suggesting an application of the IgY as both prophylactic and therapeutic treatment. Collectively, our data suggested that the P-VP8(∗) based IgY could serve as a practical approach against both NoV and RV.

Copyright © 2012 Elsevier B.V. All rights reserved.


[PubMed - as supplied by publisher]
Last modified on